MeiraGTx Holdings plc (NASDAQ:MGTX) held its annual general meeting of shareholders on Thursday. According to a press release statement and the company’s SEC filing, 75,326,022 ordinary shares were present in person or by proxy, representing approximately 81.4% of shares outstanding as of the April 21, 2026 record date.
Shareholders elected three Class II directors to serve until the 2029 annual general meeting. Ellen Hukkelhoven, Ph.D., received 63,644,550 votes in favor and 246,847 votes withheld. Nicole Seligman received 62,881,518 votes in favor and 1,009,879 votes withheld. Debra Yu, M.D., received 54,192,550 votes in favor and 9,698,847 votes withheld. Each nominee also had 11,434,625 broker non-votes.
In addition, shareholders ratified the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The proposal received 73,933,288 votes in favor, 1,029,075 votes against, and 363,659 abstentions.
The information in this article is based on a press release statement and details disclosed in a Form 8-K filing with the Securities and Exchange Commission.
In other recent news, MeiraGTx Holdings plc has announced the completion of a strategic collaboration and licensing agreement with Hologen Limited. This partnership focuses on developing gene therapies for Parkinson’s disease and genetic obesity disorders, as well as a device for delivering gene therapy to the central nervous system. Additionally, MeiraGTx has priced a public offering of 11,111,111 ordinary shares at $9.00 per share, expecting to raise approximately $100 million to fund operations and potential commercial launches into the second half of 2028.
Analysts have shown a positive outlook on MeiraGTx, with Piper Sandler raising the stock price target to $30, citing durable data for the company’s xerostomia treatment and the reacquisition of bota-vec from Johnson & Johnson. RBC Capital also increased its price target to $24, highlighting the three-year follow-up data from the Phase I xerostomia program. H.C. Wainwright reiterated a Buy rating and a $20 price target, noting progress in gene therapy and sustained clinical benefits in radiation-induced xerostomia.
These developments indicate a strategic focus on advancing gene therapy treatments and securing funding for future growth. Investors are keeping a close watch on the company’s progress in its clinical programs and partnerships.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for MGTX plus thousands of other stocks and find your next hidden gem with massive upside.